398 related articles for article (PubMed ID: 16321618)
1. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
[TBL] [Abstract][Full Text] [Related]
2. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
[TBL] [Abstract][Full Text] [Related]
3. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
Bork JA; Rogers T; Wedlund PJ; de Leon J
J Clin Psychiatry; 1999 Jul; 60(7):469-76. PubMed ID: 10453802
[TBL] [Abstract][Full Text] [Related]
4. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.
Yasui-Furukori N; Saito M; Nakagami T; Furukori H; Suzuki A; Kondo T; Kaneko S
J Psychopharmacol; 2010 Jul; 24(7):987-94. PubMed ID: 19477882
[TBL] [Abstract][Full Text] [Related]
5. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
[TBL] [Abstract][Full Text] [Related]
6. Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone.
Yasui-Furukori N; Tsuchimine S; Saito M; Nakagami T; Sugawara N; Fujii A; Kaneko S
J Clin Psychopharmacol; 2011 Oct; 31(5):633-7. PubMed ID: 21869689
[TBL] [Abstract][Full Text] [Related]
7. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes.
Ono S; Mihara K; Suzuki A; Kondo T; Yasui-Furukori N; Furukori H; de Vries R; Kaneko S
Psychopharmacology (Berl); 2002 Jun; 162(1):50-4. PubMed ID: 12107617
[TBL] [Abstract][Full Text] [Related]
8. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
Yagihashi T; Mizuno M; Chino B; Sato Y; Sakuma K; Takebayashi T; Takao T; Kosaki K
Hum Psychopharmacol; 2009 Jun; 24(4):301-8. PubMed ID: 19387994
[TBL] [Abstract][Full Text] [Related]
9. Effect of cyamemazine on the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: a preliminary retrospective study.
Lancelin F; Bourcier E; Le Masson V; Lemeille Y; Brovedani S; Paubel P; Piketty ML
Ther Drug Monit; 2010 Dec; 32(6):757-61. PubMed ID: 21068648
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
Yoshimura R; Shinkai K; Ueda N; Nakamura J
Pharmacopsychiatry; 2007 Jan; 40(1):9-13. PubMed ID: 17327954
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone.
Hendset M; Molden E; Refsum H; Hermann M
J Clin Psychopharmacol; 2009 Dec; 29(6):537-41. PubMed ID: 19910717
[TBL] [Abstract][Full Text] [Related]
12. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.
Yasui-Furukori N; Mihara K; Takahata T; Suzuki A; Nakagami T; De Vries R; Tateishi T; Kondo T; Kaneko S
Br J Clin Pharmacol; 2004 May; 57(5):569-75. PubMed ID: 15089809
[TBL] [Abstract][Full Text] [Related]
13. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone.
Kim KA; Park PW; Liu KH; Kim KB; Lee HJ; Shin JG; Park JY
J Clin Pharmacol; 2008 Jan; 48(1):66-72. PubMed ID: 18094221
[TBL] [Abstract][Full Text] [Related]
14. Influence of age and gender on risperidone plasma concentrations.
Aichhorn W; Weiss U; Marksteiner J; Kemmler G; Walch T; Zernig G; Stelzig-Schoeler R; Stuppaeck C; Geretsegger C
J Psychopharmacol; 2005 Jul; 19(4):395-401. PubMed ID: 15982995
[TBL] [Abstract][Full Text] [Related]
15. Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy.
Klampfl K; Taurines R; Preuss A; Burger R; Rothenhöfer S; Wewetzer Ch; Pfuhlmann B; Fegert J; Gerlach M; Mehler-Wex C
Pharmacopsychiatry; 2010 Mar; 43(2):58-65. PubMed ID: 20336598
[TBL] [Abstract][Full Text] [Related]
16. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
Yasui-Furukori N; Mihara K; Kondo T; Kubota T; Iga T; Takarada Y; De Vries R; Kaneko S; Tateishi T
J Clin Pharmacol; 2003 Feb; 43(2):122-7. PubMed ID: 12616663
[TBL] [Abstract][Full Text] [Related]
17. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection.
Aravagiri M; Marder SR; Wirshing D; Wirshing WC
Pharmacopsychiatry; 1998 May; 31(3):102-9. PubMed ID: 9657237
[TBL] [Abstract][Full Text] [Related]
18. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
Gunes A; Spina E; Dahl ML; Scordo MG
Ther Drug Monit; 2008 Oct; 30(5):628-33. PubMed ID: 18708991
[TBL] [Abstract][Full Text] [Related]
19. Risperidone plasma levels, clinical response and side-effects.
Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
[TBL] [Abstract][Full Text] [Related]
20. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.
Mihara K; Kondo T; Yasui-Furukori N; Suzuki A; Ishida M; Ono S; Kubota T; Iga T; Takarada Y; de Vries R; Kaneko S
Ther Drug Monit; 2003 Jun; 25(3):287-93. PubMed ID: 12766554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
